LENZ Therapeutics Inc
LENZ27.930USD
-1.790-6.02%
終値 11/03, 16:00（ET）15分遅れの株価
796.01M時価総額
損失額直近12ヶ月PER
詳細情報 LENZ Therapeutics Inc 企業名
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
LENZ Therapeutics Incの企業情報
企業コードLENZ
会社名LENZ Therapeutics Inc
上場日Jun 25, 2021
最高経営責任者「CEO」Mr. Evert (Eef) Schimmelpennink
従業員数42
証券種類Ordinary Share
決算期末Jun 25
本社所在地- -
都市- -
証券取引所NASDAQ Global Select Consolidated
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コードLENZ
上場日Jun 25, 2021
最高経営責任者「CEO」Mr. Evert (Eef) Schimmelpennink
LENZ Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
620.60K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
620.60K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sun, Aug 24
更新時刻: Sun, Aug 24
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
10.10%
Ridgeback Capital Management, L.P.
6.84%
Paradigm BioCapital Advisors LP
6.02%
他の
49.72%
株主統計
株主統計
比率
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
10.10%
Ridgeback Capital Management, L.P.
6.84%
Paradigm BioCapital Advisors LP
6.02%
他の
49.72%
種類
株主統計
比率
Venture Capital
38.62%
Hedge Fund
27.55%
Investment Advisor
23.95%
Investment Advisor/Hedge Fund
14.32%
Individual Investor
2.73%
Research Firm
2.25%
Bank and Trust
0.14%
Pension Fund
0.06%
Insurance Company
0.02%
機関投資家保有株
更新時刻: Sun, Oct 5
更新時刻: Sun, Oct 5
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
261
30.52M
107.02%
+1.08M
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
Adage Capital Management, L.P.
1.12M
3.94%
+585.00K
+108.79%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Sectoral Asset Management Inc.
977.25K
3.43%
--
--
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sun, Nov 2
更新時刻: Sun, Nov 2
銘柄名
比率
SPDR S&P Pharmaceuticals ETF
1.7%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.28%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
0.43%
iShares U.S. Pharmaceuticals ETF
0.34%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Biotechnology ETF
0.11%
詳細を見る
SPDR S&P Pharmaceuticals ETF
比率1.7%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.28%
Virtus LifeSci Biotech Clinical Trials ETF
比率1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.43%
iShares U.S. Pharmaceuticals ETF
比率0.34%
iShares Micro-Cap ETF
比率0.16%
Invesco Nasdaq Biotechnology ETF
比率0.14%
ProShares Ultra Nasdaq Biotechnology
比率0.14%
iShares Biotechnology ETF
比率0.11%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
日付
種類
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
